Molecular cancer therapeutics

Testing the cancer-fighting effects of the WEE1 blocker MK-1775 on its own

Updated

Abstract

MK-1775, a WEE1 inhibitor, is cytotoxic across a broad panel of tumor cell lines and induces DNA double-strand breaks.

  • WEE1 inhibition abrogates cell-cycle arrest and proper DNA repair, enhancing genotoxic chemotherapy effectiveness.
  • MK-1775 treatment induces DNA damage in S-phase cells without the need for additional chemotherapy or radiation.
  • At tolerated doses, MK-1775 leads to tumor growth inhibition or regression in xenograft models.
  • Knockdown of PKMYT1 reduces the effective concentration of MK-1775 by five-fold and increases DNA damage markers.
  • In a study of 305 cell lines, 73% of the 33 most sensitive lines had below-average expression of PKMYT1.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free